IL17A and lupus nephritis: Study SELUNE (NCT04181762), a phase III randomized, double-blind trial, aims to investigate the efficacy and safety of secukinumab, an anti-IL-17A monoclonal antibody, in combination with the standard of care therapy in patients with active lupus nephritis.